```html

Vaccine‑Associated Paralytic Poliomyelitis (VAPP)

Overview

Vaccine‑associated paralytic poliomyelitis (VAPP) is a rare adverse event in which the live‑attenuated oral poliovirus vaccine (OPV) reverts to a neurovirulent form and causes paralysis that mimics wild‑type poliomyelitis. The condition can occur in the vaccine recipient or, less commonly, in close contacts who acquire the vaccine‑derived virus through fecal‑oral transmission.

• Who it affects: Primarily infants and children under five years of age who receive OPV, but adults who are close contacts (e.g., siblings, caregivers) can also develop VAPP.
• Prevalence: In the United States, the risk of VAPP after a full OPV series is about 1 case per 2.4 million doses administered – the lowest reported worldwide (CDC, 2023). Global estimates vary; the World Health Organization (WHO) estimates 2–5 VAPP cases per million OPV doses in areas with low immunisation coverage.
• Geographic distribution: VAPP is essentially eliminated in countries that have switched solely to inactivated poliovirus vaccine (IPV); it remains a concern only in regions where OPV is still used for polio eradication campaigns.

Symptoms

The clinical picture of VAPP mirrors that of wild‑type poliomyelitis and follows three classic patterns:

1. Typical (non‑paralytic) poliomyelitis

• Fever (often 38–40 °C) lasting 1–3 days
• Headache, malaise, and sore throat
• Gastro‑intestinal upset (nausea, vomiting, abdominal pain)
• Rarely, a mild aseptic meningitis

2. Paralytic poliomyelitis (most common presentation of VAPP)

• Asymmetric limb weakness – usually sudden onset, affecting one or more extremities.
• Flaccid paralysis – loss of muscle tone, reflexes, and voluntary movement.
• Facial or bulbar weakness – difficulty swallowing, drooling, or nasal speech.
• Respiratory muscle involvement – rapid breathing, chest wall weakness, or need for ventilatory support.
• Pain or paresthesia in the affected limb(s), though pain is less prominent than in other neuropathies.

3. Acute flaccid myelitis‑like syndrome

• Rapid progression over 24‑48 hours
• Involvement of both upper and lower motor neurons
• Little to no sensory loss, distinguishing it from Guillain‑Barré syndrome.

Symptoms typically appear 7–21 days after the last OPV dose, but onset can be as early as 4 days or as late as 30 days.

Causes and Risk Factors

Underlying cause

OPV contains three attenuated Sabin strains (type 1, 2, 3). In rare circumstances the virus mutates during replication in the gut, regaining neurovirulence. If the virus reaches the central nervous system, it destroys motor neurons in the anterior horn of the spinal cord, producing paralysis.

Key risk factors

• Age: Children <5 years have the highest susceptibility due to immature immune systems.
• Immunodeficiency: Primary (e.g., agammaglobulinemia) or secondary (e.g., HIV, chemotherapy) immune deficits increase the chance of prolonged viral replication and mutation.
• Intestinal co‑infection: Enteric infections (e.g., rotavirus, helminths) can facilitate viral replication.
• High OPV dose density: Receiving multiple OPV doses within a short interval raises cumulative exposure.
• Close contact exposure: Household members of a recently vaccinated infant can acquire vaccine‑derived virus, especially in poor sanitation settings.

Diagnosis

Diagnosis is clinical, supported by laboratory studies that demonstrate poliovirus in stool, throat swab, or cerebrospinal fluid (CSF) and rule out other causes of acute flaccid paralysis.

Step‑by‑step diagnostic approach

1. History & physical examination: Document recent OPV administration (date, lot number), symptom onset, and pattern of weakness.
2. Neurological exam: Assess motor strength, reflexes, cranial nerve function, and respiratory status.
3. Stool specimen (collected on ≥2 separate days within 14 days of onset): PCR and viral culture to isolate poliovirus.
4. Throat swab: Supplemental PCR if stool is negative.
5. CSF analysis (lumbar puncture): Usually shows mild pleocytosis (10–100 cells/µL) with normal glucose and protein; PCR can detect poliovirus RNA.
6. Electrodiagnostic studies (EMG/nerve conduction): Reveal acute denervation consistent with anterior horn cell loss.
7. Imaging: MRI of the spine may show T2 hyperintensity in the anterior horn but is not required for diagnosis.

To confirm VAPP, the isolated virus must be genetically related to the OPV strain and show markers of reversion to neurovirulence (e.g., the VP1 region mutations). The CDC’s Laboratory‑Based Surveillance of Vaccine‑Derived Polioviruses provides detailed criteria.

Treatment Options

There is no antiviral that specifically eradicates vaccine‑derived poliovirus; treatment is largely supportive.

Acute management

• Respiratory support: Mechanical ventilation for patients with diaphragmatic or intercostal weakness; monitor oxygen saturation continuously.
• Physical therapy (within 48 hours of onset): Gentle range‑of‑motion exercises to maintain joint flexibility and prevent contractures.
• Immunoglobulin therapy: Intravenous immunoglobulin (IVIG) may be considered in immunodeficient patients to boost neutralising antibodies, though evidence is limited.
• Pain management: Acetaminophen or NSAIDs for mild pain; opioids only if severe.

Long‑term care

• Rehabilitation: Structured physiotherapy, occupational therapy, and, when needed, orthotic devices to maximise functional recovery.
• Assistive technology: Wheelchairs, gait trainers, or speech devices for bulbar involvement.
• Vaccination strategy: Switch to IPV series for future immunisations; avoid additional OPV doses.

Living with Vaccine‑Associated Paralytic Poliomyelitis

While many patients achieve partial or full recovery, a multidisciplinary approach helps maintain independence and quality of life.

• Regular follow‑up: Neurology visits every 3–6 months in the first year, then annually.
• Home exercise program: Daily stretching, strengthening, and gait training under therapist guidance.
• Nutrition: High‑protein diet to support muscle repair; consider a dietitian if dysphagia is present.
• Psychosocial support: Counseling for anxiety or depression, especially in children facing school accommodations.
• Vaccination record update: Ensure the patient receives a complete IPV series; keep documentation for school or travel purposes.
• Community resources: Connect with polio survivor networks (e.g., Global Polio Eradication Initiative) for peer support.

Prevention

Because VAPP occurs only with OPV, the most effective preventive measure is the global transition to IPV.

• Use IPV exclusively in routine immunisations (the United States, most high‑income countries, and many middle‑income nations have already done this).
• Maintain high OPV coverage where it is still needed for eradication, to limit circulation of vaccine‑derived polioviruses (VDPVs).
• Improve sanitation: Safe water, proper hand‑washing, and sewage treatment reduce fecal‑oral spread.
• Screen for immunodeficiency before OPV administration in outbreak settings; consider IPV for at‑risk individuals.
• Surveillance: Prompt stool testing of any acute flaccid paralysis case helps detect VDPVs early.

Complications

If not managed promptly, VAPP can lead to serious sequelae:

• Permanent muscle weakness or contractures, especially in lower limbs.
• Respiratory failure requiring prolonged ventilation.
• Bulbar dysfunction leading to aspiration pneumonia.
• Orthopedic deformities such as scoliosis or hip dysplasia.
• Psychological impact including anxiety, depression, or post‑traumatic stress.

When to Seek Emergency Care

---

References:

• Centers for Disease Control and Prevention. “Polio Vaccine–Associated Paralytic Poliomyelitis.” 2023. CDC
• World Health Organization. “Vaccine‑Derived Polioviruses (VDPVs).” 2022. WHO
• Mayo Clinic. “Poliomyelitis (Polio).” 2024. Mayo Clinic
• Cleveland Clinic. “Acute Flaccid Myelitis and Polio.” 2023. Cleveland Clinic
• National Institutes of Health. “Oral Polio Vaccine and Vaccine‑Derived Polioviruses.” 2022. NIH

```